Crossmark

A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Crossref DOI link: https://doi.org/10.1016/j.anpede.2017.03.001

Published Print: 2018-02

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Navas-López, Víctor Manuel

Pujol-Muncunill, Gemma

Llerena, Enrique

Navalón Rubio, María

Gil-Ortega, David

Varea-Calderón, Vicente

Sierra Salinas, Carlos

Martin-de-Carpi, Javier
License Information

Text and Data Mining valid from 2018-02-01
More Information

This article is maintained by: Elsevier

Article Title: A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease

Journal Title: Anales de Pediatría (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.anpede.2017.03.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.anpedi.2017.01.013

Content Type: article

Copyright: © 2016 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.